Phase
Condition
Muscular Dystrophy
Aging
Polymyositis (Inflammatory Muscle Disease)
Treatment
Placebo
Mitopure (Urolithin A)
Clinical Study ID
Ages 65-85 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Frail (as defined by the Fried frailty criteria)nonsmoking participants in the agegroup of 65 to 85 years old, both male and female.
A body mass index between 18 to 35 kg/m2.
Not on any medications/living with medical conditions that would compromise thestudy outcome or the safety of the research participant.
Able to participate and willing to give written informed consent and to comply withthe study restrictions.
Willing to be assigned randomly either to the UA or the control group.
Exclusion
Exclusion Criteria:
Participants must not have:
Participated in a clinical trial within 90 days of screening or more than 4 times inthe previous year.
A history (within 3 months of screening) of alcohol consumption exceeding 2 standarddrinks per day on average (1 standard drink = 10 grams of alcohol).
A history or presence of allergy to 5-aminolevulinic acid or porphyrins.
A history or presence of allergy to lidocaine.
Positive hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), orhuman immunodeficiency virus antibody (HIV Ab) at screening.
Unwillingness or inability to refrain from consuming alcohol within 48 hours beforeeach visit until the end of said visit.
Unwillingness or inability to refrain from consuming 8 or more units of xanthinecontaining beverages and foods per day during the entire study.
Unwillingness to not consume other mitochondrial supplements during the course ofthe study (such as CoQ10, reseveratrol, NR, NMN etc.) and pomegranate juice
unwillingness to not change diet or physical activity levels during the course ofthe study
Unwillingness or inability to undergo a muscle biopsy.
Underlying chronic disease, which in the opinion of the investigator, wouldinterfere with study participation or the validity of the measurements.
Unintentional weight loss ≤5% of regular body weight during the last 6 months.
Medication requirements that may interfere with the interpretation of the results.
Loss or donation of blood over 500mL three months prior (male subjects) or fourmonths prior (female subjects) to participating in the study.
Smoked (tobacco and/or marijuana mixed with tobacco (THC)) within 6 months prior tothe start of the study;
Abused drugs, medicine or alcohol within up to 30 days prior to the start of thestudy (Alcohol: more than 10 drinks a week, with more than 2 drinks a day most days;Drugs: THC, cocaine, opiates, amphetamines/methamphetamines, benzodiazepines,barbiturates, Buprenorphine, Creatin, Methadone metabolite, oxycodone,phencyclidine);
A positive COVID-19 test taken 1 week to 24h before study start date.
Study Design
Connect with a study center
McGill University Health Center
Montréal,
CanadaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.